Effective surgical treatment of obesity may be mediated by ablation of the lipogenic gut hormone gastric inhibitory polypeptide (GIP): evidence and clinical opportunity for development of new obesity-diabetes drugs?
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Roux-en-Y bypass surgery is increasingly used for treatment of gross obesity due to the general inability of lifestyle change and existing drug treatments to counter the obesity epidemic. This common form of bariatric surgery involves bypass of the small intestine with significant reduction of body of weight that is independent of malabsorption. Strikingly, obesity-related diabetes is also cured by the procedure but prior to body weight loss. This is due to rapid improvement of insulin resistance and associated pancreatic beta-cell function. Several hypotheses have been proposed to account for this phenomenon, but the most attractive concerns surgical ablation of gastric inhibitory polypetide (GIP)-secreting intestinal K-cells. Thus, circulating GIP levels are decreased after Roux-en-Y bypass surgery and GIP is known to play a key role in lipid metabolism and fat deposition. Further, both genetic and chemical ablation of GIP in animal models has been shown to protect against obesity and associated metabolic disturbances. These observations in animals and man suggest that GIP receptor antagonism may afford an alternative therapeutic option for treatment of obesity-diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Roux, C. W. L., Aylwin, S. J. B., Batterham, R. L., Borg, C. M., Coyle, F., Prasad, V., Shurey, S., Ghatei, M. A., Patel, A. G., & Bloom, S. R. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000183349.16877.84 · Cited by 985
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 2×
“Degradation: cleaved to inactive GIP(3-42) by dipeptidyl”
BackgroundPoitout, V., & Robertson, R. P. (2002) · Endocrinology · doi:10.1210/endo.143.2.8623 · Cited by 743
Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure
Hansotia, T., Maida, A., Flock, G., Yamada, Y., Tsukiyama, K., Seino, Y., & Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci25483 · Cited by 290
Gumbs, A. A., Modlin, I. M., & Ballantyne, G. H. (2005) · Obesity Surgery · doi:10.1381/0960892053723367 · Cited by 188
Cited by
Musso, G., Gambino, R., Pacini, G., De Michieli, F., & Cassader, M. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26720 · Cited by 107
Flatt, P. R. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02455.x · Cited by 68
Self-citationEnteroendocrine hormone mimetics for the treatment of obesity and diabetes
Irwin, N., & Flatt, P. R. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.09.009 · Cited by 41
Self-citationVogel, C. I., Scherag, A., Brönner, G., Nguyen, T. T., Wang, H.-J., Grallert, H., Bornhorst, A., Rosskopf, D., Völzke, H., Reinehr, T., et al. (2009) · BMC Medical Genetics · doi:10.1186/1471-2350-10-19 · Cited by 30
Irwin, N., Gault, V. A., O’Harte, F. P. M., & Flatt, P. R. (2020) · Peptides · doi:10.1016/j.peptides.2019.170203 · Cited by 27
Self-citation
Metadata
- Authors
- Flatt, P. R.
- Venue
- Diabetes and Vascular Disease Research
- Publisher
- SAGE Publications
- Published
- 2007-06
- Volume
- 4
- Issue
- 2
- Pages
- 150-152
- ISSN
- 1479-1641 (ISSN-L)
- 1752-8984
- OpenAlex
- W2157607499
- Cited by
- 47
- References
- 6
- FWCI
- 6.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effective surgical treatment of obesity may be mediated by ablation of the lipogenic gut hormone gastric inhibitory polypeptide (GIP): evidence and clinical opportunity for development of new obesity-diabetes drugs? https://app.cochat.ai/papers/10.3132/dvdr.2007.034
- The paper
- Flatt, P. R. (2007). Effective surgical treatment of obesity may be mediated by ablation of the lipogenic gut hormone gastric inhibitory polypeptide (GIP): evidence and clinical opportunity for development of new obesity-diabetes drugs? Diabetes and Vascular Disease Research. https://doi.org/10.3132/dvdr.2007.034
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.